A cautious pricing strategy paid off for TopoTarget A/S, as its initial public offering of 10 million shares on the Copenhagen Stock Exchange, which yielded gross proceeds of DKK225 million (US$36.5 million), was more than six times over-subscribed. (BioWorld International)

A cautious pricing strategy paid off for TopoTarget A/S, as its initial public offering of 10 million shares on the Copenhagen Stock Exchange, which yielded gross proceeds of DKK225 million (US$36.5 million), was more than six times over-subscribed. (BioWorld International)

Exiqon A/S secured $20 million in its third funding round to continue development of its miRCURY portfolio of microRNA tools, to expand its sales and marketing capabilities, to fund new production facilities and to retire debt. (BioWorld International)

Exiqon A/S secured $20 million in its third funding round to continue development of its miRCURY portfolio of microRNA tools, to expand its sales and marketing capabilities, to fund new production facilities and to retire debt. (BioWorld International)